WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ESPR past revenue growth

How has ESPR's revenue growth performed historically?
Company
54.14%
Industry
10.18%
Market
17.2%
ESPR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ESPR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ESPR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ESPR earnings and revenue history

Current Revenue
$116.3M
Current Earnings
-$209.2M
Current Profit Margin
-179.9%

ESPR Return on Equity

Insufficient data to display

Be the first to know when ESPR announces earnings.

ESPR Return on Assets

Current Company
-91.6%
Current Industry
3.4%
ESPR is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ESPR Return on Capital Employed

Current Company
-303.14%
Current Industry
5.1%
ESPR's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ESPR vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ESPR$116.33M-$150.11M-$209.25M-5.90%N/A
HROW$130.19M$9.95M-$24.41M+25.77%N/A
ACB$199.23M-$66.17M-$106.90M+17.87%N/A
PROC$414.10M$75.58M$52.20M-61.31%-38.62%
ORGO$433.14M$36.03M$4.95M+17.49%-90.86%
View Top Pharmaceutical Stocks

ESPR earnings dates

Next earnings date
May 7, 2024

Esperion Therapeutics Earnings & Revenue FAQ

What were ESPR's earnings last quarter?

On Invalid Date, Esperion Therapeutics (NASDAQ: ESPR) reported Q4 2023 earnings per share (EPS) of -$0.50, up 32.43% year over year. Total Esperion Therapeutics earnings for the quarter were -$56.34 million. In the same quarter last year, Esperion Therapeutics's earnings per share (EPS) was -$0.74.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.

What was ESPR's earnings growth in the past year?

As of Q2 2024, Esperion Therapeutics's earnings has grown year over year. Esperion Therapeutics's earnings in the past year totalled -$209.25 million.

What is ESPR's earnings date?

Esperion Therapeutics's earnings date is Invalid Date. Add ESPR to your watchlist to be reminded of ESPR's next earnings announcement.

What was ESPR's revenue last quarter?

On Invalid Date, Esperion Therapeutics (NASDAQ: ESPR) reported Q4 2023 revenue of $32.25 million up 71.38% year over year. In the same quarter last year, Esperion Therapeutics's revenue was $18.82 million.

What was ESPR's revenue growth in the past year?

As of Q2 2024, Esperion Therapeutics's revenue has grown 54.14% year over year. This is 43.95 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.18%. Esperion Therapeutics's revenue in the past year totalled $116.33 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.